$-0.35 EPS Expected for Nektar Therapeutics (NKTR); Partner Fund Management LP Has Increased Acorda Therapeutics (ACOR) Holding By $33.68 Million

February 19, 2018 - By Vivian Park

Analysts expect Nektar Therapeutics (NASDAQ:NKTR) to report $-0.35 EPS on March, 7.They anticipate $0.07 EPS change or 25.00% from last quarter’s $-0.28 EPS. After having $0.37 EPS previously, Nektar Therapeutics’s analysts see -194.59% EPS growth. The stock increased 1.57% or $1.29 during the last trading session, reaching $83.43. About 2.34M shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 41.52% since February 19, 2017 and is uptrending. It has outperformed by 24.82% the S&P500.

Partner Fund Management Lp increased Acorda Therapeutics Inc (ACOR) stake by 56.57% reported in 2017Q3 SEC filing. Partner Fund Management Lp acquired 1.46M shares as Acorda Therapeutics Inc (ACOR)’s stock declined 39.72%. The Partner Fund Management Lp holds 4.05M shares with $95.84M value, up from 2.59M last quarter. Acorda Therapeutics Inc now has $1.21 billion valuation. The stock increased 2.79% or $0.7 during the last trading session, reaching $25.8. About 645,771 shares traded. Acorda Therapeutics, Inc. (NASDAQ:ACOR) has declined 40.68% since February 19, 2017 and is downtrending. It has underperformed by 57.38% the S&P500.

Among 14 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 5 have Buy rating, 1 Sell and 8 Hold. Therefore 36% are positive. Acorda Therapeutics had 43 analyst reports since August 25, 2015 according to SRatingsIntel. As per Tuesday, August 25, the company rating was maintained by Cowen & Co. The rating was maintained by Oppenheimer on Wednesday, January 31 with “Perform”. The rating was downgraded by Stifel Nicolaus on Thursday, November 16 to “Hold”. Cantor Fitzgerald maintained Acorda Therapeutics, Inc. (NASDAQ:ACOR) rating on Thursday, July 27. Cantor Fitzgerald has “Hold” rating and $1800 target. On Wednesday, November 15 the stock rating was maintained by Jefferies with “Hold”. Aegis Capital maintained it with “Buy” rating and $52 target in Wednesday, January 6 report. As per Tuesday, October 31, the company rating was maintained by Cantor Fitzgerald. Raymond James initiated the shares of ACOR in report on Tuesday, September 1 with “Market Perform” rating. On Tuesday, November 28 the stock rating was initiated by Piper Jaffray with “Hold”. The stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) has “Buy” rating given on Tuesday, August 25 by Stifel Nicolaus.

Investors sentiment decreased to 1.22 in Q3 2017. Its down 0.03, from 1.25 in 2017Q2. It dived, as 19 investors sold ACOR shares while 39 reduced holdings. 22 funds opened positions while 49 raised stakes. 51.31 million shares or 4.56% more from 49.07 million shares in 2017Q2 were reported. Natixis holds 12,824 shares. State Teachers Retirement Systems invested in 0% or 59,217 shares. Focused Wealth Mgmt holds 0.01% or 1,000 shares. American Grp Inc invested 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Pnc Services Grp has invested 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Jabre Cap Partners Sa, a Switzerland-based fund reported 60,000 shares. 78,030 are held by Morgan Stanley. Invesco invested 0.01% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Wells Fargo Mn reported 85,357 shares stake. Mason Street Advsrs Limited Liability holds 0.01% or 11,815 shares in its portfolio. Citigroup holds 0% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 71,814 shares. Prelude Cap Management Limited Com invested 0.01% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Sector Pension Invest Board has invested 0% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Guggenheim Cap Ltd Liability Com invested 0.01% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Parkside National Bank & Trust reported 42 shares.

Since August 29, 2017, it had 1 insider buy, and 3 selling transactions for $12.92 million activity. LAWRENCE DAVID sold 250 shares worth $6,350. 34,520 shares were sold by Wasman Jane, worth $952,319 on Friday, January 19. SCOPIA CAPITAL MANAGEMENT LP also bought $14.73M worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) on Tuesday, August 29.

Partner Fund Management Lp decreased Servicenow Inc (NYSE:NOW) stake by 91,546 shares to 527,190 valued at $61.96 million in 2017Q3. It also reduced Molina Healthcare Inc (Call) (NYSE:MOH) stake by 390,102 shares and now owns 490,300 shares. Myokardia Inc was reduced too.

Since September 6, 2017, it had 0 buys, and 12 insider sales for $23.49 million activity. Another trade for 5,000 shares valued at $109,850 was sold by Lingnau Lutz. The insider ROBIN HOWARD W sold $1.79M. Labrucherie Gil M sold 120,000 shares worth $2.93M. Another trade for 100,000 shares valued at $2.41 million was made by Gergel Ivan P. on Friday, September 29. $139,008 worth of stock was sold by CHESS ROBERT on Thursday, September 21. On Friday, September 22 the insider KUEBLER CHRISTOPHER A sold $87,440. $189,575 worth of Nektar Therapeutics (NASDAQ:NKTR) shares were sold by Hora Maninder.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $13.14 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

Investors sentiment decreased to 1.4 in 2017 Q3. Its down 0.49, from 1.89 in 2017Q2. It worsened, as 15 investors sold Nektar Therapeutics shares while 52 reduced holdings. 26 funds opened positions while 68 raised stakes. 148.76 million shares or 1.09% more from 147.16 million shares in 2017Q2 were reported. Blackrock reported 21.00 million shares or 0.03% of all its holdings. Harvey Capital Management Inc stated it has 2.78% in Nektar Therapeutics (NASDAQ:NKTR). J Goldman And Company Lp holds 243,100 shares or 0.29% of its portfolio. First Republic Invest Mgmt has 25,864 shares for 0% of their portfolio. Amalgamated National Bank stated it has 0.02% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Fic reported 85,556 shares. Moreover, Voya Inv Ltd has 0% invested in Nektar Therapeutics (NASDAQ:NKTR). Schwab Charles Mngmt holds 703,282 shares or 0.01% of its portfolio. Employees Retirement Association Of Colorado stated it has 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Legal & General Gru Public Lc holds 306,478 shares or 0.01% of its portfolio. Tci Wealth Advsr Inc holds 0% or 192 shares. Prelude Cap Mngmt Llc accumulated 16,587 shares. Balyasny Asset Management Ltd Limited Liability Company reported 792,782 shares. Camber Management Lc reported 7.91% in Nektar Therapeutics (NASDAQ:NKTR). Aperio Grp Inc Ltd Liability holds 43,485 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>